Related Experiment Video
Updated: Mar 5, 2026
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy
Yi-Fan Chen1,2, Li-Hsien Chen1, Yu-Min Yeh3
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Taiwan.
Abstract:
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment. No medication has been shown to be effective in the treatment of CIPN. This study aims to integrate the image-based high-content screening, mouse behavior models and mechanistic cell-based assays to discover potential neuroprotective drugs. Among screened compounds, minoxidil showed the most potent neuroprotective effect against paclitaxel, with regard to neurite outgrowth of dorsal root ganglia (DRG). Minoxidil protected mice from thermal insensitivity and alleviated mechanical allodynia in paclitaxel-treated mice. The ultrastructure and quantified G-ratio of myelin integrity of sciatic nerve tissues supported the observations in mouse behavioral tests. The mechanistic study on DRG neurons suggested that minoxidil suppressed neuroinflammation and remodeled the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, minoxidil showed a synergistic anti-tumor effect with paclitaxel both in tumor xenograft models of cervical and breast cancer. Interestingly, the quantitative assays on hair length and hair growth both exhibited that minoxidil significantly improved the hair quality after chemotherapy. Since minoxidil is a drug approved by the Food and Drug Administration (FDA), the safety and biocompatibility are well documented. The immediate next step is to launch an early-stage clinical trial intending to prevent CIPN by minoxidil.
Insights
Minoxidil effectively protects against chemotherapy-induced peripheral neuropathy (CIPN) by preserving nerve integrity and reducing inflammation. This FDA-approved drug also enhances hair regrowth and shows synergistic anti-tumor effects, paving the way for clinical trials.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of cancer treatment.
- Current treatments lack efficacy in managing CIPN.
- There is a critical need for novel therapeutic strategies to prevent or treat CIPN.
Purpose of the Study:
- To discover and validate neuroprotective drugs for CIPN using a multi-modal screening approach.
- To investigate the therapeutic potential of minoxidil in preclinical models of CIPN.
- To evaluate the synergistic anti-tumor and hair regrowth effects of minoxidil in combination with chemotherapy.
Main Methods:
- Integrated image-based high-content screening, mouse behavior models, and mechanistic cell-based assays.
- Assessed neuroprotection via neurite outgrowth in dorsal root ganglia (DRG) neurons.
- Evaluated minoxidil's effects on thermal sensitivity, mechanical allodynia, sciatic nerve ultrastructure, neuroinflammation, and intracellular calcium homeostasis in paclitaxel-treated mice.
- Investigated synergistic anti-tumor activity in cervical and breast cancer xenograft models.
- Quantified minoxidil's impact on hair growth post-chemotherapy.
Main Results:
- Minoxidil demonstrated potent neuroprotective effects against paclitaxel-induced damage, preserving DRG neurite outgrowth.
- Minoxidil treatment ameliorated thermal insensitivity and mechanical allodynia in mice.
- Sciatic nerve analysis confirmed myelin integrity preservation.
- Mechanistic studies revealed minoxidil suppressed neuroinflammation and normalized calcium dysregulation.
- Minoxidil exhibited synergistic anti-tumor effects with paclitaxel and significantly improved chemotherapy-induced hair loss.
Conclusions:
- Minoxidil is a promising therapeutic agent for preventing and treating CIPN.
- Its neuroprotective mechanisms involve suppressing neuroinflammation and restoring calcium homeostasis.
- Minoxidil offers dual benefits of CIPN management and synergistic anti-cancer activity.
- Given its FDA approval and safety profile, minoxidil warrants clinical investigation for CIPN prevention.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:23Antihypertensive Drugs: Vasodilators